Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Methotrexate Stories

2009-04-09 03:43:00

JAKARTA, Indonesia, April 9 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints. The most visible symptoms of RA are swollen joints and crippling stiffness, particularly of the hands and feet. It can cause fatigue, fever, loss of appetite and also impedes mobility and quality of life. (Logo:...

2009-01-28 08:50:00

Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemiaScientists from St. Jude Children's Research Hospital and the Children's Oncology Group (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic variations that clinicians might be able to use as guideposts for designing more effective chemotherapy for this...

2009-01-27 15:00:00

Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemia MEMPHIS, Tenn., Jan. 27 /PRNewswire-USNewswire/ -- Scientists from St. Jude Children's Research Hospital and the Children's Oncology Group (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic variations that clinicians might be able to use as...

2009-01-14 09:12:50

Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. It enters the cell via several pathways, one of which involves folate receptor ÃŽ² (FRÃŽ²), which is highly specific for cells present in the joints of patients with rheumatoid arthritis (RA). During the last two decades, a second generation of folate antagonists has been designed to address...

2009-01-08 12:15:00

The life of a Minnesota boy suffering with a rare and serious form of the genetic disorder Pompe disease has been extended after treatment with a drug typically used to suppress the immune system of those with cancer and rheumatoid arthritis.Rituxan, or rituximab,  is a monoclonal antibody made by Genentech Inc and Biogen Idec.  It consists of genetically engineered immune system molecules, and is used to treat non-Hodgkin's lymphoma, rheumatoid arthritis and other conditions.Dr....

2008-12-04 00:30:00

NUTLEY, N.J., Dec. 4 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration (FDA) has provided further guidance on the requirements for the Biologics License Application (BLA) for ACTEMRA(R) (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). As a result of the FDA's evolving Risk Evaluation and Mitigation Strategy (REMS)...

2008-11-13 09:00:37

CHARLOTTE, N.C., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has begun dosing volunteers in the single ascending dose (SAD) study of its Phase I clinical program for CH-4051, the second drug candidate from its portfolio of orally available, non-metabolized antifolates engineered to provide potent anti-inflammatory activity without the liver and kidney toxicities or tolerability related side effects associated with chronic methotrexate (MTX)...

2008-11-07 09:00:24

Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI) announced today that the Centers for Medicare and Medicaid Services (CMS), under the Medicare Part B benefit, has assigned a unique, product-specific billing code, or J-code, for FUSILEV(TM) (levoleucovorin). FUSILEV(TM) is the only commercially available formulation comprised only of the pharmacologically active isomer of leucovorin. The J-code J06410 becomes effective on January 1, 2009, and will assist providers in obtaining reimbursement for...

2008-10-31 09:00:08

Spectrum Pharmaceuticals, Inc., (NasdaqGM:SPPI) today announced that it has filed with the FDA the supplemental NDA for FUSILEV(TM) (levoleucovorin) for injection in combination with 5-FU containing regimens in advanced metastatic colorectal cancer. FUSILEV is the only commercially available formulation comprised only of the pharmacologically active isomer of leucovorin. "Ninety percent of the more than 500 million milligrams of leucovorin used in the United States is for colorectal...

2008-10-30 03:00:27

Chelsea Therapeutics International has completed patient enrollment in its Phase II trial comparing the efficacy and tolerability of daily oral doses of CH-1504, a metabolically inert antifolate, to a standard weekly dose of methotrexate in rheumatoid arthritis patients. A total of 200 patients were enrolled in this 12-week, four-arm, parallel group Phase II clinical trial designed comparing 0.25mg, 0.5mg and 1mg once daily oral doses of CH-1504 versus a 20mg once weekly oral dose of...